

Nihar R Desai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8322460/publications.pdf>

Version: 2024-02-01

209
papers

5,057
citations

147801

31
h-index

123424

61
g-index

213
all docs

213
docs citations

213
times ranked

7781
citing authors

#	ARTICLE	IF	CITATIONS
1	National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013. JAMA Cardiology, 2017, 2, 56.	6.1	297
2	Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA - Journal of the American Medical Association, 2020, 323, 734.	7.4	260
3	Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions. JAMA - Journal of the American Medical Association, 2016, 316, 2647.	7.4	230
4	Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2015, 314, 2045.	7.4	212
5	Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation Quality and Cost Implications. American Journal of Medicine, 2014, 127, 1075-1082.e1.	1.5	199
6	Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge. JAMA - Journal of the American Medical Association, 2017, 318, 270.	7.4	176
7	Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ, The, 2016, 352, i637.	6.0	165
8	Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease. Journal of the American College of Cardiology, 2014, 63, 520-527.	2.8	152
9	Machine Learning Prediction of Mortality and Hospitalization in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 12-21.	4.1	152
10	Inferior Vena Cava Filters to Prevent Pulmonary Embolism. Journal of the American College of Cardiology, 2017, 70, 1587-1597.	2.8	134
11	Use of Machine Learning Models to Predict Death After Acute Myocardial Infarction. JAMA Cardiology, 2021, 6, 633.	6.1	116
12	National Trends in Atrial Fibrillation Hospitalization, Readmission, and Mortality for Medicare Beneficiaries, 1999-2013. Circulation, 2017, 135, 1227-1239.	1.6	110
13	Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	3.7	100
14	Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice. Journal of the American College of Cardiology, 2022, 79, 2203-2213.	2.8	86
15	Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. European Journal of Heart Failure, 2019, 21, 1064-1078.	7.1	79
16	Geographic Variation in Trends and Disparities in Acute Myocardial Infarction Hospitalization and Mortality by Income Levels, 1999-2013. JAMA Cardiology, 2016, 1, 255.	6.1	64
17	Trends in Short- and Long-Term Outcomes for Takotsubo Cardiomyopathy Among Medicare Fee-for-Service Beneficiaries, 2007 to 2012. JACC: Heart Failure, 2016, 4, 197-205.	4.1	64
18	Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy. JACC: Heart Failure, 2021, 9, 420-429.	4.1	64

#	ARTICLE	IF	CITATIONS
19	Vena Caval Filter Utilization and Outcomes in Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1027-1035.	2.8	61
20	Comparison of Machine Learning Methods With National Cardiovascular Data Registry Models for Prediction of Risk of Bleeding After Percutaneous Coronary Intervention. <i>JAMA Network Open</i> , 2019, 2, e196835.	5.9	60
21	Financial Hardship From Medical Bills Among Nonelderly U.S. Adults With Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 727-732.	2.8	56
22	National Trends in Use and Outcomes of Pulmonary Artery Catheters Among Medicare Beneficiaries, 1999-2013. <i>JAMA Cardiology</i> , 2017, 2, 908.	6.1	54
23	Use of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>JAMA Network Open</i> , 2021, 4, e2037748.	5.9	54
24	Predictive Abilities of Machine Learning Techniques May Be Limited by Dataset Characteristics: Insights From the UNOS Database. <i>Journal of Cardiac Failure</i> , 2019, 25, 479-483.	1.7	48
25	Overview and experience of the YODA Project with clinical trial data sharing after 5 years. <i>Scientific Data</i> , 2018, 5, 180268.	5.3	48
26	Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. <i>Trials</i> , 2017, 18, 333.	1.6	43
27	The Evolving Management of Aortic Valve Disease: 5-Year Trends in SAVR, TAVR, and Medical Therapy. <i>American Journal of Cardiology</i> , 2019, 124, 763-771.	1.6	42
28	Procedural Patterns and Safety of Atrial Fibrillation Ablation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007944.	4.8	42
29	Sex and Race Differences in the Utilization and Outcomes of Coronary Artery Bypass Grafting Among Medicare Beneficiaries, 1999-2014. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	40
30	Trends in Heart Failure Hospitalizations in the US from 2008 to 2018. <i>Journal of Cardiac Failure</i> , 2022, 28, 171-180.	1.7	40
31	Trajectories of Risk for Specific Readmission Diagnoses after Hospitalization for Heart Failure, Acute Myocardial Infarction, or Pneumonia. <i>PLoS ONE</i> , 2016, 11, e0160492.	2.5	39
32	Sex Differences in Patients Receiving Left Ventricular Assist Devices for End-Stage Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 770-779.	4.1	36
33	Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2021, 10, e021084.	3.7	35
34	Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0243291.	2.5	31
35	Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004054.	2.2	30
36	Clinical Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside Hemodynamic Profiles. <i>PLoS ONE</i> , 2016, 11, e0145881.	2.5	30

#	ARTICLE	IF	CITATIONS
37	Trends in Cardiovascular Health of US Adults by Income, 2005-2014. <i>JAMA Cardiology</i> , 2017, 2, 814.	6.1	28
38	Contemporary risk model for in-hospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry—Get With The Guidelines (GWTG)®. <i>American Heart Journal</i> , 2017, 194, 16-24.	2.7	28
39	Industry Payments to Cardiologists. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e005016.	2.2	28
40	Trends in 30-Day Readmission Rates for Medicare and Non-Medicare Patients in the Era of the Affordable Care Act. <i>American Journal of Medicine</i> , 2018, 131, 1324-1331.e14.	1.5	28
41	Persistent socioeconomic disparities in cardiovascular risk factors and health in the United States: Medical Expenditure Panel Survey 2002–2013. <i>Atherosclerosis</i> , 2018, 269, 301-305.	0.8	27
42	Association Between Industry Payments to Physicians and Device Selection in ICD Implantation. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1755.	7.4	26
43	The impact of heart failure on patients and caregivers: A qualitative study. <i>PLoS ONE</i> , 2021, 16, e0248240.	2.5	26
44	Clinical Outcomes After Left Ventricular Assist Device Implantation in Older Adults. <i>JACC: Heart Failure</i> , 2019, 7, 1069-1078.	4.1	25
45	Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry). <i>American Journal of Cardiology</i> , 2021, 146, 99-106.	1.6	25
46	PCSK9 inhibition in patients with hypercholesterolemia. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 567-574.	4.9	24
47	Data sharing through an NIH central database repository: a cross-sectional survey of BioLINCC users. <i>BMJ Open</i> , 2016, 6, e012769.	1.9	24
48	Age of Data at the Time of Publication of Contemporary Clinical Trials. <i>JAMA Network Open</i> , 2018, 1, e181065.	5.9	23
49	Digoxin Use and Associated Adverse Events Among Older Adults. <i>American Journal of Medicine</i> , 2019, 132, 1191-1198.	1.5	23
50	Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. <i>JAMA Cardiology</i> , 2017, 2, 556.	6.1	22
51	The Impact of the Transition From Volume to Value on Heart Failure Care: Implications of Novel Payment Models and Quality Improvement Initiatives. <i>Journal of Cardiac Failure</i> , 2017, 23, 615-620.	1.7	22
52	Variation in the Use of Warfarin and Direct Oral Anticoagulants in Atrial Fibrillation and Associated Cost Implications. <i>American Journal of Medicine</i> , 2019, 132, 61-70.e1.	1.5	22
53	Relative Costs of Surgical and Transcatheter Aortic Valve Replacement and Medical Therapy. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008681.	3.9	22
54	National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	21

#	ARTICLE	IF	CITATIONS
55	Revascularization Practices and Outcomes in Patients With Multivessel Coronary Artery Disease Who Presented With Acute Myocardial Infarction and Cardiogenic Shock in the US, 2009-2018. <i>JAMA Internal Medicine</i> , 2020, 180, 1317.	5.1	21
56	Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States. <i>JACC: CardioOncology</i> , 2021, 3, 236-246.	4.0	21
57	COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system. <i>PLoS ONE</i> , 2020, 15, e0238829.	2.5	21
58	Reporting of Noninferiority Trials in ClinicalTrials.gov and Corresponding Publications. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1163.	7.4	20
59	Hospital Characteristics Associated With Postdischarge Hospital Readmission, Observation, and Emergency Department Utilization. <i>Medical Care</i> , 2018, 56, 281-289.	2.4	20
60	Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006515.	2.2	20
61	Cardiovascular Toxicities of Androgen Deprivation Therapy. <i>Current Treatment Options in Oncology</i> , 2021, 22, 47.	3.0	20
62	Prevention of atherosclerotic cardiovascular disease in South Asians in the US: A clinical perspective from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2021, 15, 402-422.	1.5	20
63	Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 545-556.	2.2	20
64	Trends in Performance and Opportunities for Improvement on a Composite Measure of Acute Myocardial Infarction Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004983.	2.2	19
65	Outcomes after observation stays among older adult Medicare beneficiaries in the USA: retrospective cohort study. <i>BMJ: British Medical Journal</i> , 2017, 357, j2616.	2.3	18
66	Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). <i>Journal of Urology</i> , 2021, 206, 613-622.	0.4	18
67	National Trends in Healthcare-Associated Infections for Five Common Cardiovascular Conditions. <i>American Journal of Cardiology</i> , 2019, 124, 1140-1148.	1.6	17
68	Transition From an Open to Closed Staffing Model in the Cardiac Intensive Care Unit Improves Clinical Outcomes. <i>Journal of the American Heart Association</i> , 2021, 10, e018182.	3.7	17
69	Outcomes of mechanical circulatory support for acute myocardial infarction complicated by cardiogenic shock. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 658-663.	1.7	17
70	Strength of Evidence Underlying the American Heart Association/American College of Cardiology Guidelines on Endovascular and Surgical Treatment of Peripheral Vascular Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007244.	3.9	16
71	Evaluation of Hospital Performance Using the Excess Days in Acute Care Measure in the Hospital Readmissions Reduction Program. <i>Annals of Internal Medicine</i> , 2021, 174, 86-92.	3.9	16
72	National Quality Assessment of Early Clopidogrel Therapy in Chinese Patients With Acute Myocardial Infarction (AMI) in 2006 and 2011: Insights From the China Patient-Centered Evaluative Assessment of Cardiac Events (PEACE) Retrospective AMI Study. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	15

#	ARTICLE	IF	CITATIONS
73	Availability of Clinical Trial Data From Industry-Sponsored Cardiovascular Trials. <i>Journal of the American Heart Association</i> , 2016, 5, e003307.	3.7	15
74	Switching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registry. <i>Clinical Cardiology</i> , 2020, 43, 743-751.	1.8	15
75	Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort. <i>Journal of Clinical Lipidology</i> , 2020, 14, 695-706.e4.	1.5	15
76	Impact of <i>CYP2C19</i> Genetic Testing on Provider Prescribing Patterns for Antiplatelet Therapy After Acute Coronary Syndromes and Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 694-699.	2.2	14
77	Association of the US Department of Justice Investigation of Implantable Cardioverter-Defibrillators and Devices Not Meeting the Medicare National Coverage Determination, 2007-2015. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 63.	7.4	14
78	Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization. <i>PLoS ONE</i> , 2020, 15, e0226844.	2.5	14
79	National Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart Failure. <i>Journal of the American Heart Association</i> , 2021, 10, e019412.	3.7	14
80	REVeAL-HF. <i>JACC: Heart Failure</i> , 2021, 9, 409-419.	4.1	14
81	Forgone Medical Care Associated With Increased Health Care Costs Among the U.S. Heart Failure Population. <i>JACC: Heart Failure</i> , 2021, 9, 710-719.	4.1	14
82	Trends in Early Aspirin Use Among Patients With Acute Myocardial Infarction in China, 2001-2011: The China PEACE Retrospective AMI Study. <i>Journal of the American Heart Association</i> , 2014, 3, e001250.	3.7	13
83	National assessment of early β -blocker therapy in patients with acute myocardial infarction in China, 2001-2011: The China Patient-centered Evaluative Assessment of Cardiac Events (PEACE) Retrospective AMI Study. <i>American Heart Journal</i> , 2015, 170, 506-515.e1.	2.7	13
84	Are non-ST-segment elevation myocardial infarctions missing in China?. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2017, 3, 319-327.	4.0	13
85	National Trends in Incidence and Outcomes of Patients With Heart Failure Requiring Respiratory Support. <i>American Journal of Cardiology</i> , 2019, 124, 1712-1719.	1.6	13
86	Clinical Implications of Respiratory Failure in Patients Receiving Durable Left Ventricular Assist Devices for End-Stage Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e006369.	3.9	13
87	Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation. <i>American Journal of Cardiology</i> , 2020, 133, 116-125.	1.6	13
88	Quadruple Therapy Is the New Standard of Care for HFrEF. <i>JACC: Heart Failure</i> , 2020, 8, 819-821.	4.1	13
89	Association between Respiratory Failure and Clinical Outcomes in Patients with Acute Heart Failure: Analysis of 5 Pooled Clinical Trials. <i>Journal of Cardiac Failure</i> , 2021, 27, 602-606.	1.7	13
90	Trends in transcatheter and surgical aortic valve replacement in the United States, 2008-2018. <i>American Heart Journal</i> , 2022, 243, 87-91.	2.7	13

#	ARTICLE	IF	CITATIONS
91	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 908-918.	2.7	13
92	National Institutes of Health Career Development Awards for Cardiovascular“Physician”Scientists. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1816-1827.	2.8	12
93	National Landscape of Unplanned 30-Day Readmissions in Patients With Left Ventricular Assist Device Implantation. <i>American Journal of Cardiology</i> , 2018, 122, 261-267.	1.6	12
94	Early Experiences With Journal Data Sharing Policies: A Survey of Published Clinical Trial Investigators. <i>Annals of Internal Medicine</i> , 2018, 169, 586.	3.9	12
95	Financial barriers in accessing medical care for peripheral artery disease are associated with delay of presentation and adverse health status outcomes in the United States. <i>Vascular Medicine</i> , 2020, 25, 13-24.	1.5	12
96	National Trends in Hospital Readmission Rates among Medicare Fee-for-Service Survivors of Mitral Valve Surgery, 1999“2010. <i>PLoS ONE</i> , 2015, 10, e0132470.	2.5	12
97	Rationale and design of a cluster-randomized pragmatic trial aimed at improving use of guideline directed medical therapy in outpatients with heart failure: PRagmatic trial of messaging to providers about treatment of heart failure (PROMPT-HF). <i>American Heart Journal</i> , 2022, 244, 107-115.	2.7	12
98	A Blueprint for the Post Discharge Clinic Visit after an Admission for Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2017, 60, 237-248.	3.1	11
99	Data Sharing and Cardiology. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3018-3025.	2.8	11
100	Favorable Modifiable Cardiovascular Risk Profile Is Associated With Lower Healthcare Costs Among Cancer Patients: The 2012“2013 Medical Expenditure Panel Survey. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	11
101	The Twittersphere Needs Academic“Cardiologists!. <i>JACC: Heart Failure</i> , 2018, 6, 172-173.	4.1	11
102	Transition to Advanced Therapies in Elderly Patients Supported by Extracorporeal Membrane Oxygenation Therapy. <i>Journal of Cardiac Failure</i> , 2020, 26, 1086-1089.	1.7	11
103	Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies. <i>PLoS ONE</i> , 2021, 16, e0247789.	2.5	11
104	Insurance and Prehospital Delay in Patients “55“Years With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2015, 116, 1827-1832.	1.6	10
105	National Assessment of Statin Therapy in Patients Hospitalized with Acute Myocardial Infarction: Insight from China PEACE-Retrospective AMI Study, 2001, 2006, 2011. <i>PLoS ONE</i> , 2016, 11, e0150806.	2.5	10
106	Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. <i>Journal of the American Heart Association</i> , 2020, 9, e013606.	3.7	10
107	Cardio-obstetrics: Recognizing and managing cardiovascular complications of pregnancy. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 43-52.	1.3	10
108	Impact of Obesity on Heart Transplantation Outcomes. <i>Journal of the American Heart Association</i> , 2021, 10, e021346.	3.7	10

#	ARTICLE	IF	CITATIONS
109	Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 232-243.	1.0	9
110	Can machine learning complement traditional medical device surveillance? A case-study of dual-chamber implantable cardioverter–defibrillators. <i>Medical Devices: Evidence and Research</i> , 2017, Volume 10, 165-188.	0.8	9
111	Variation in and Hospital Characteristics Associated With the Value of Care for Medicare Beneficiaries With Acute Myocardial Infarction, Heart Failure, and Pneumonia. <i>JAMA Network Open</i> , 2018, 1, e183519.	5.9	9
112	Distribution of Industry Payments Among Medical Directors of Catheterization and Electrophysiology Laboratories From the Top 100 US Hospitals. <i>JAMA Internal Medicine</i> , 2019, 179, 1282.	5.1	9
113	Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure. <i>PLoS ONE</i> , 2020, 15, e0242928.	2.5	9
114	<scp>Costâ€effectiveness</scp> of <scp>secondâ€line</scp> empagliflozin versus liraglutide for type 2 diabetes in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 652-661.	4.4	9
115	Association of Hospital Payment Profiles With Variation in 30-Day Medicare Cost for Inpatients With Heart Failure or Pneumonia. <i>JAMA Network Open</i> , 2019, 2, e1915604.	5.9	8
116	Relationship Between Patient-Reported Hospital Experience and 30-Day Mortality and Readmission Rates for Acute Myocardial Infarction, Heart Failure, and Pneumonia. <i>Journal of General Internal Medicine</i> , 2019, 34, 526-528.	2.6	8
117	Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes. <i>Journal of the American Heart Association</i> , 2019, 8, e010373.	3.7	8
118	Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump for Cardiogenic Shockâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 303.	7.4	8
119	Mechanical ventilation at the time of heart transplantation and associations with clinical outcomes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 843-851.	1.0	8
120	Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes. <i>JACC: Heart Failure</i> , 2021, 9, 568-577.	4.1	8
121	Trends in Cardiac Biomarker Testing in China for Patients with Acute Myocardial Infarction, 2001 to 2011: China PEACE-Retrospective AMI Study. <i>PLoS ONE</i> , 2015, 10, e0122237.	2.5	8
122	Reimagining Evidence Generation for Heart Failure and the Role of Integrated Health Care Systems. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, CIRCOUTCOMES121008292.	2.2	8
123	Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. <i>Open Heart</i> , 2021, 8, e001849.	2.3	8
124	National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patientâ€centered Evaluation Assessment of Cardiac Events (PEACE)â€Retrospective AMI Study, 2001, 2006, and 2011. <i>Journal of the American Heart Association</i> , 2015, 4, e001718.	3.7	7
125	Practiceâ€Level Variation in Outpatient Cardiac Care and Association With Outcomes. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	7
126	PCI Appropriateness in New York. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1243-1246.	2.8	7

#	ARTICLE	IF	CITATIONS
127	Essential Elements of Early Post Discharge Care of Patients with Heart Failure. <i>Current Heart Failure Reports</i> , 2018, 15, 181-190.	3.3	7
128	Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. <i>JAMA Network Open</i> , 2019, 2, e1913553.	5.9	7
129	Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT). <i>American Journal of Cardiology</i> , 2019, 123, 1193-1201.	1.6	7
130	Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 447-455.	2.4	7
131	Outcomes in patients with anthracycline-induced cardiomyopathy undergoing left ventricular assist devices implantation. <i>ESC Heart Failure</i> , 2021, 8, 2866-2875.	3.1	7
132	Association of obesity with venous thromboembolism and myocardial injury in COVID-19. <i>Obesity Research and Clinical Practice</i> , 2021, 15, 512-514.	1.8	7
133	US False Claims Act Investigations of Unnecessary Percutaneous Coronary Interventions. <i>JAMA Internal Medicine</i> , 2020, 180, 1534.	5.1	6
134	Physician variation in the de-adoption of ineffective statin and fibrate therapy. <i>Health Services Research</i> , 2021, 56, 919-931.	2.0	6
135	Obesity and the Bidirectional Risk of Cancer and Cardiovascular Diseases in African Americans: Disparity vs. Ancestry. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 761488.	2.4	6
136	Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit. <i>Clinical Therapeutics</i> , 2022, 44, 52-66.e2.	2.5	6
137	Diabetes Care Among Older Adults Enrolled in Medicare Advantage Versus Traditional Medicare Fee-For-Service Plans: The Diabetes Collaborative Registry. <i>Diabetes Care</i> , 2022, 45, 1549-1557.	8.6	6
138	Obstacles to Developing Cost-Lowering Health Technology. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1447.	7.4	5
139	Alirocumab's Price Reduction. <i>Circulation</i> , 2018, 138, 1502-1504.	1.6	5
140	Association of access to exercise opportunities and cardiovascular mortality. <i>American Heart Journal</i> , 2019, 212, 152-156.	2.7	5
141	Assessing cardiovascular risk in cancer patients: opportunities and challenges. <i>European Journal of Preventive Cardiology</i> , 2021, 28, e45-e46.	1.8	5
142	A Novel Treatment for a Rare Cause of Cardiogenic Shock. <i>JACC: Case Reports</i> , 2020, 2, 1461-1465.	0.6	5
143	Healthcare utilization and expenditures associated with hyperkalemia management: a retrospective study of Medicare Advantage patients. <i>Journal of Medical Economics</i> , 2021, 24, 1025-1036.	2.1	5
144	Effect of institutional transcatheter aortic valve replacement volume on mortality: A systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E453-E461.	1.7	5

#	ARTICLE	IF	CITATIONS
145	Low-density lipoprotein cholesterol lowering in real-world patients treated with evolocumab. <i>Clinical Cardiology</i> , 2021, 44, 715-722.	1.8	5
146	Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 497-505.	4.1	5
147	Electronic health record risk score provides earlier prognostication of clinical outcomes in patients admitted to the cardiac intensive care unit. <i>American Heart Journal</i> , 2021, 238, 85-88.	2.7	5
148	Trends and Outcomes of Cardiac Transplantation in the Lowest Urgency Candidates. <i>Journal of the American Heart Association</i> , 2021, 10, e023662.	3.7	5
149	Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study. <i>Cardiology and Therapy</i> , 2022, 11, 249-267.	2.6	5
150	Managing the Economic Challenges in the Treatment of Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2018, 61, 476-483.	3.1	4
151	Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 1325-1332.	2.0	4
152	Patient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm. <i>International Journal of Health Economics and Management</i> , 2020, 20, 299-317.	1.1	4
153	Patient and hospital characteristics associated with ticagrelor uptake in acute MI: An analysis of the Chest Painâ€“MI Registry. <i>International Journal of Cardiology</i> , 2020, 304, 14-20.	1.7	4
154	Preexisting frailty and outcomes in older patients with acute myocardial infarction. <i>American Heart Journal</i> , 2022, 249, 34-44.	2.7	4
155	Managing the economic challenges in the treatment of heart failure. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 612.	1.7	4
156	Assessing Hospital Performance for Emerging Technologies. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 498-500.	2.2	3
157	Variation in practice patterns and outcomes across United Network for Organ Sharing allocation regions. <i>Clinical Cardiology</i> , 2018, 41, 81-86.	1.8	3
158	Development and Testing of Improved Models to Predict Payment Using Centers for Medicare & Medicaid Services Claims Data. <i>JAMA Network Open</i> , 2019, 2, e198406.	5.9	3
159	Association of in-hospital resource utilization with post-acute spending in Medicare beneficiaries hospitalized for acute myocardial infarction: a cross-sectional study. <i>BMC Health Services Research</i> , 2019, 19, 190.	2.2	3
160	Socio-Economic Burden of Myocardial Infarction Among Cancer Patients. <i>American Journal of Cardiology</i> , 2021, 141, 16-22.	1.6	3
161	Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007759.	3.9	3
162	Brief report: Cannabis and opioid use disorder among heart failure admissions, 2008â€“2018. <i>PLoS ONE</i> , 2021, 16, e0255514.	2.5	3

#	ARTICLE	IF	CITATIONS
163	Serum Potassium and Mortality in High-Risk Patients: SPRINT. <i>Hypertension</i> , 2021, 78, 1586-1594.	2.7	3
164	The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population. <i>American Health and Drug Benefits</i> , 2019, 12, 352-361.	0.5	3
165	Thirty-Day and 90-Day Episode of Care Spending Following Heart Failure Hospitalization Among Medicare Beneficiaries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, .	2.2	3
166	Patterns of Institutional Review of Percutaneous Coronary Intervention Appropriateness and the Effect on Quality of Care and Clinical Outcomes. <i>JAMA Internal Medicine</i> , 2015, 175, 1988.	5.1	2
167	The Quality Chasm Between Administrative Coding and Accurate Phenotyping of Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 490-492.	1.7	2
168	Patterns of Care for Atrial Fibrillation Before, During, and at Discharge From Hospitalization. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009003.	4.8	2
169	The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 1359-1366.	1.7	2
170	Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapy (RE-LY) trial. <i>PLoS ONE</i> , 2021, 16, e0256338.	2.5	2
171	Cannabis use disorder among atrial fibrillation admissions, 2008â€“2018. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 1934-1938.	1.2	2
172	Achievement and quality measure attainment in patients hospitalized with atrial fibrillation: Results from The Get With The Guidelines â€“ Atrial Fibrillation (GWTC-AFIB) registry. <i>American Heart Journal</i> , 2022, 245, 90-99.	2.7	2
173	Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 185-187.	4.1	1
174	Outpatient Cost-effectiveness Study of Hyperkalemia Management. <i>Journal of Cardiac Failure</i> , 2020, 26, S115.	1.7	1
175	Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer. <i>American Heart Journal</i> , 2020, 230, 54-58.	2.7	1
176	Adoption of sacubitril-valsartan in the Medicare population. <i>American Heart Journal</i> , 2020, 223, 81-83.	2.7	1
177	The effect of catheter-directed thrombolytic use on readmission rates and in-hospital outcomes among cancer patients with venous thromboembolism in the United States. <i>Journal of Cardiac Surgery</i> , 2020, 35, 609-611.	0.7	1
178	Impact of left ventricular assist devices and heart transplants on acute myocardial infarction and heart failure mortality and readmission measures. <i>PLoS ONE</i> , 2020, 15, e0230734.	2.5	1
179	Association of vitamins, minerals, and lead with lipoprotein(a) in a cross-sectional cohort of US adults. <i>International Journal for Vitamin and Nutrition Research</i> , 2023, 93, 99-110.	1.5	1
180	Comparison of Transcatheter and Open Mitral Valve Repair Among Patients With Mitral Regurgitation. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1522-1529.	3.0	1

#	ARTICLE	IF	CITATIONS
181	Policy and Payment Challenges in the Postpandemic Treatment of Heart Failure: Value-Based Care and Telehealth. <i>Journal of Cardiac Failure</i> , 2022, 28, 835-844.	1.7	1
182	Longitudinal Outcomes Associated With Non-Evidence-Based Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries (From the National Cardiovascular Data Registry). <i>American Journal of Cardiology</i> , 2021, 155, 64-71.	1.6	1
183	Association Between Hospital Performance Metrics and Market Share. <i>JAMA Network Open</i> , 2021, 4, e2130353.	5.9	1
184	Patterns of care for first-detected atrial fibrillation: Insights from the Get With The Guidelines® Atrial Fibrillation registry. <i>Heart Rhythm</i> , 2022, 19, 1049-1057.	0.7	1
185	Reducing Cardiovascular Risk in the Medicare Million Hearts Risk Reduction Model: Insights From the National Cardiovascular Data Registry PINNACLE Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, CIRCOUTCOMES121007908.	2.2	1
186	Toward evidence-based health care delivery reform. <i>American Heart Journal</i> , 2016, 174, 154-156.	2.7	0
187	The Reply. <i>American Journal of Medicine</i> , 2019, 132, e723.	1.5	0
188	Coronary artery bypass grafting surgery versus percutaneous coronary intervention for coronary artery disease. <i>The Cochrane Library</i> , 2019, , .	2.8	0
189	Relationship Between Provider Experience and Cardiac Performance Measures in Outpatients (from) Tj ETQq1 1 0.784314 rgBT /Over 1.6	1.6	0
190	Use and outcomes of wearable cardioverter-defibrillators in a large integrated academic health system. <i>American Heart Journal</i> , 2020, 226, 232-234.	2.7	0
191	Readmission after inferior vena cava filter placement for acute venous thromboembolism in the United States: Impact of a cancer diagnosis. <i>Journal of Cardiac Surgery</i> , 2020, 35, 2275-2278.	0.7	0
192	Medical Student Patient Outreach to Ensure Continuity of Care During the COVID-19 Pandemic. <i>Telemedicine Reports</i> , 2021, 2, 56-63.	0.7	0
193	Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial. <i>BMC Nephrology</i> , 2021, 22, 284.	1.8	0
194	Physician Network Connections Associated With Faster De-Adoption of Dronedaronone for Permanent Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008040.	2.2	0
195	Trends in ICD Implantations and In-Hospital Outcomes after DOJ Investigation. <i>Journal of Cardiac Failure</i> , 2021, , .	1.7	0
196	From Reactivity to Proactivity. <i>JACC: Heart Failure</i> , 2020, 8, 1035-1037.	4.1	0
197	Increased Dropout Rates in Model Year 4 of the Bundled Payments for Care Improvement Advanced Model. <i>Journal of General Internal Medicine</i> , 2022, , .	2.6	0
198	Comfort Measures Only in Myocardial Infarction: Prevalence of This Status, Change Over Time, and Predictors From a Nationwide Study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, e007610.	2.2	0

#	ARTICLE	IF	CITATIONS
199	Hospital Characteristics and Early Enrollment Trends in the American College of Cardiology Voluntary Public Reporting Program. JAMA Network Open, 2022, 5, e2147903.	5.9	0
200	Title is missing!., 2020, 15, e0230734.		0
201	Title is missing!., 2020, 15, e0230734.		0
202	Title is missing!., 2020, 15, e0230734.		0
203	Title is missing!., 2020, 15, e0230734.		0
204	Title is missing!., 2020, 15, e0230734.		0
205	Title is missing!., 2020, 15, e0230734.		0
206	Title is missing!., 2020, 15, e0238829.		0
207	Title is missing!., 2020, 15, e0238829.		0
208	Title is missing!., 2020, 15, e0238829.		0
209	Title is missing!., 2020, 15, e0238829.		0